As only a few trials have examined BMD and fracture risk in diabetic (Grey et al., 2013) and insulin-resistant patients, (Bone et al., 2013; Bray et al., 2013), evaluating the long-term skeletal impact of pioglitazone remains a critical safety concern post-stroke. The gene discussed is INS; the disease is stroke disorder.